Stay updated on PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FVBJZIyilW3Ua775hZCkbidr-iUU.uncropped.jpg&w=3840&q=75)
Latest updates to the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 13 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the webpage content related to the study evaluating the effectiveness of treatment for Glioblastoma / Gliosarcoma through the suppression of the PI3K/Akt pathway compared with MK-3475 (Pembrolizumab).SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Genetic and Rare Diseases Information Center resources: Glioblastoma Gliosarcoma Glioma Neuroepithelioma Drug Information available for: Pembrolizumab FDA Drug and Device Resources Show less'. This change indicates a shift in the displayed content from showing more details to showing less information related to genetic and rare diseases, specifically focusing on resources for Glioblastoma, Gliosarcoma, Glioma, Neuroepithelioma, and Drug Information for Pembrolizumab.SummaryDifference23%
Stay in the know with updates to PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PI3K/Akt Suppression vs MK-3475 in Glioblastoma Clinical Trial page.